Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 4 1

Status

Completed 4Recruiting 1

Sponsor Class

OTHER 16INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 3Tumor-Agnostic 1NET 1Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Breast Neoplasms 3Prostatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Brain Neoplasms 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × gadobutrol × Clear all
NCT04373564 2026-01-22

ODYSSEY

Guerbet

Phase 4 Recruiting
2,076 enrolled
BreastEndocrineGastrointestinalGenitourinaryNET

Breast Neoplasms, Carcinoma, Hepatocellular, Prostatic Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors

NCT00522951 2017-08-28

SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study

Bayer

Phase 3 Completed
165 enrolled 24 charts
CNS

Brain Neoplasms

NCT01050829 2014-12-30

Gadobutrol Magnevist-controlled Body Study

Bayer

Phase 3 Completed
370 enrolled
Tumor-Agnostic

Neoplasms

NCT01067976 2014-11-11

Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI

Bayer

Phase 3 Completed
446 enrolled 30 charts
Breast

Breast Neoplasms

NCT01104584 2014-11-11

GEMMA 2

Bayer

Phase 3 Completed
460 enrolled 31 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡